Literature DB >> 10205014

The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores.

M T Teh1, D Sugden.   

Abstract

1. GR128107 (3-(1-acetyl-3-methyl-piperidine)-5-methoxyindole) has previously been reported to be a competitive melatonin receptor antagonist in blocking melatonin inhibition of [3H]-dopamine release from rabbit retina, a response mediated by the MT2 receptor subtype. 2. GR128107, like melatonin, induced a rapid (maximum response in 60-90 min) pigment aggregation in a clonal line of Xenopus laevis melanophores. GR128107 behaved as a partial agonist (pEC50 8.58+/-0.03, n=3) with an Emax of 0.83 (relative to melatonin, pEC50 10.09+/-0.03, n=3). 3. The concentration-response curve for pigment granule aggregation to both melatonin and GR128107 was displaced in a parallel, rightward manner by melatonin receptor antagonists with very similar potencies; estimated pKB RJ252 (against melatonin 4.60/against GR128107 4.54) < GR135533 (6.40/6.14) < Luzindole (6.45/6.49) < S20929 (6.58/6.65) < 4-P-PDOT (6.73/6.85). 4. Both melatonin- and GR128107-induced pigment granule aggregation was prevented by pretreatment of melanophores with pertussis toxin (10-1000 ng ml(-1)). 5. Prolonged pre-treatment of melanophores with melatonin desensitized the pigment aggregation response to GR128107. In desensitized cells, the maximal aggregation produced by GR128107 was only 0.27+/-0.01 (n=4) and the pEC50 was reduced (vehicle 8.57+/-0.12; melatonin pre-treated 7.84+/-0.09, n=4). The maximal response to melatonin in desensitized melanophores was unchanged but the pEC50 was reduced (vehicle 10.49+/-0.03; melatonin pre-treated 9.83+/-0.04, n=4). 6. These results demonstrate that GR128107 induces pigment granule aggregation in Xenopus melanophores by activating a cell membrane melatonin receptor coupled via a pertussis toxin-sensitive G-protein. 7. The partial agonist activity of GR128107 in melanophores may be apparent because of the very high density of melatonin receptors in these cells (Bmax 1223 fmol mg protein(-1)) compared to the low density of sites in rabbit retina (Bmax 3.1 fmol mg protein(-1)). This suggestion is supported by the finding that GR128107, like melatonin, acted as a full agonist and inhibited forskolin-stimulation of cyclic AMP accumulation in NIH-3T3 cells expressing a high density of human mt1 or MT2 receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205014      PMCID: PMC1565880          DOI: 10.1038/sj.bjp.0702404

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Melanophore pigment dispersion responses to agonists show two patterns of sensitivity to inhibitors of cAMP-dependent protein kinase and protein kinase C.

Authors:  T S McClintock; J P Rising; M R Lerner
Journal:  J Cell Physiol       Date:  1996-04       Impact factor: 6.384

2.  Melatonin directly constricts rat cerebral arteries through modulation of potassium channels.

Authors:  G G Geary; D N Krause; S P Duckles
Journal:  Am J Physiol       Date:  1997-09

3.  The melatonin receptor in the human brain: cloning experiments and distribution studies.

Authors:  C Mazzucchelli; M Pannacci; R Nonno; V Lucini; F Fraschini; B M Stankov
Journal:  Brain Res Mol Brain Res       Date:  1996-07

4.  Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide.

Authors:  M A Pappolla; M Sos; R A Omar; R J Bick; D L Hickson-Bick; R J Reiter; S Efthimiopoulos; N K Robakis
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

5.  Analogues of diverse structure are unable to differentiate native melatonin receptors in the chicken retina, sheep pars tuberalis and Xenopus melanophores.

Authors:  H Pickering; S Sword; S Vonhoff; R Jones; D Sugden
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

6.  Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor.

Authors:  M L Dubocovich; M I Masana; S Iacob; D M Sauri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-03       Impact factor: 3.000

7.  Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats.

Authors:  K N Ting; W R Dunn; D J Davies; D Sugden; P Delagrange; B Guardiola-Lemaître; E Scalbert; V G Wilson
Journal:  Br J Pharmacol       Date:  1997-12       Impact factor: 8.739

Review 8.  A review of the evidence supporting melatonin's role as an antioxidant.

Authors:  R J Reiter; D Melchiorri; E Sewerynek; B Poeggeler; L Barlow-Walden; J Chuang; G G Ortiz; D Acuña-Castroviejo
Journal:  J Pineal Res       Date:  1995-01       Impact factor: 13.007

9.  Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor.

Authors:  S M Reppert; C Godson; C D Mahle; D R Weaver; S A Slaugenhaupt; J F Gusella
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Melatonin phase advances circadian rhythm.

Authors:  M E Attenburrow; B A Dowling; P A Sargent; A L Sharpley; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

View more
  3 in total

1.  An endogenous 5-HT(7) receptor mediates pigment granule dispersion in Xenopus laevis melanophores.

Authors:  M T Teh; D Sugden
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

3.  Melatonin.

Authors:  Paul Pévet
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.